Frontlight ResearchEarly access
Thalassaemia trials in United States
19 of 28 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
- Where
- Atlanta, Dallas, New York, Philadelphia
- Age
- 1 year to 17 years
- People
- 54 worldwide
- Run by
- Agios Pharmaceuticals, Inc.
See details and how to joinNCT07506863 · EU 2025-524707-71-00 - Phase 3Taking peopleA Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia
- Where
- Atlanta, Dallas, New York, Palo Alto, Philadelphia
- Age
- 1 year to 17 years
- People
- 45 worldwide
- Run by
- Agios Pharmaceuticals, Inc.
See details and how to joinNCT07517133 · EU 2025-524706-15-00 - Phase 1/2Taking peopleRepeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels
- Where
- Bethesda
- Age
- 2 years to 80 years
- People
- 32
- Run by
- National Heart, Lung, and Blood Institute (NHLBI)
See details and how to joinNCT04008368 - Phase 2Taking peopleAlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
- Where
- Valhalla
- Age
- 1 day to 30 years
- People
- 20
- Run by
- Mitchell Cairo
See details and how to joinNCT04099966 - Phase 1/2Taking peoplePartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
- Where
- Bethesda
- Age
- 4 years to 65 years
- People
- 90
- Run by
- National Heart, Lung, and Blood Institute (NHLBI)
See details and how to joinNCT07599176 - Early phase 1Taking peopleDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
- Where
- Bethesda
- Age
- 18 years to 100 years
- People
- 100
- Run by
- National Heart, Lung, and Blood Institute (NHLBI)
See details and how to joinNCT06313398 - Phase 3Taking peopleA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- Atlanta, Augusta, Birmingham, Boston, Brooklyn, Charleston, Charlotte, Chicago, Cincinnati, Durham, Farmington, Greenville, Hollywood, Houston, Los Angeles, Memphis, Miami, Milwaukee, New Orleans, New York, North Canton, Oakland, Orange, Phoenix, Richmond, St Louis, Tacoma, The Bronx, Washington D.C., Winston-Salem
- Age
- 2 years and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - Phase 1/2Taking peopleT-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
- Where
- Pittsburgh
- Age
- 5 years to 40 years
- People
- 5
- Run by
- Paul Szabolcs
See details and how to joinNCT03653338 - Phase 3Enrolling by invitationA Long-term Follow-up Study in Participants Who Received CTX001
- Where
- Charlotte, Chicago, Memphis, Nashville, New York, Palo Alto, Philadelphia, San Antonio
- Age
- 2 years to 64 years
- People
- 160 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04208529 · EU 2024-512654-19-00 - Phase 2Taking peopleMyeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
- Where
- Gainesville, Los Angeles, Milwaukee, Valhalla
- Age
- 6 months to 21 years
- People
- 40
- Run by
- New York Medical College
See details and how to joinNCT02675959 - Phase 2Taking peopleStudy of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- Where
- Los Angeles, New York
- Age
- 6 years to 17 years
- People
- 99 worldwide
- Run by
- Celgene
See details and how to joinNCT04143724 · EU 2022-502499-22-00 - Phase 3CompletedA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- Where
- Boston, Chicago, Cleveland, Detroit, Houston, Los Angeles, Nashville, New York, Oakland, Philadelphia, Stanford, Tampa
- Age
- 18 years and over
- People
- 665 worldwide
- Run by
- Celgene
See details and how to joinNCT04064060 - Phase 2Taking peopleA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
- Where
- Basking Ridge, Commack, Harrison, Middletown, Montvale, Rockville Centre
- Age
- 2 years to 50 years
- People
- 24
- Run by
- Memorial Sloan Kettering Cancer Center
See details and how to joinNCT05736419 - Phase 3Taking peopleEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- Where
- Charlotte, Nashville, New York
- Age
- 12 years to 35 years
- People
- 26 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT05477563 · EU 2024-514641-12-00 - Phase 1Taking peopleHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
- Where
- Boston
- Age
- 13 years to 40 years
- People
- 10
- Run by
- Daniel Bauer
See details and how to joinNCT06647979 - Phase 1Taking peopleStudy of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- Where
- Augusta
- Age
- 18 years and over
- People
- 18
- Run by
- Abdullah Kutlar
See details and how to joinNCT01245179 - Phase 2Taking peopleReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- Where
- Pittsburgh
- Age
- 2 months to 55 years
- People
- 100
- Run by
- Paul Szabolcs
See details and how to joinNCT01962415 - Phase 4Taking peopleEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)
- Where
- Cincinnati
- Age
- 6 months and over
- People
- 50
- Run by
- Children's Hospital Medical Center, Cincinnati
See details and how to joinNCT07177300 - Phase 1/2Enrolling by invitationThe BENeFiTS Trial in Beta Thalassemia Intermedia
- Where
- Boston, New York, Oakland, Weston
- Age
- 18 years and over
- People
- 36 worldwide
- Run by
- Phoenicia BioScience
See details and how to joinNCT04432623